CAMBRIDGE, United Kingdom, April 16, 2026 (GLOBE NEWSWIRE) -- STORM Therapeutics Ltd. (STORM), the clinical stage company targeting RNA modifications to reprogram cells and develop novel cancer ...
Storm Therapeutics raises $56M in Series C funding to accelerate cancer therapy development and expand its innovative RNA-targeting platform.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results